FLT3 is a type III receptor tyrosine kinase and plays an important role in survival, proliferation, and differentiation of hematopoietic cells, and is most frequently mutated and is a poor prognostic factor in AML patients (Kiyoi et al., 2020). This evidence concerns the gene FLT3 and acute myeloid leukemia.